Group 1 - The core focus of Telix Pharmaceuticals Ltd. is on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies [1] - A class action has been filed on behalf of all investors who purchased or acquired Telix securities during the class period from February 21, 2025, to August 28, 2025 [1]

Core Insights - Telix Pharmaceuticals Limited will participate in the UBS Global Healthcare Conference and the Jefferies Global Healthcare Conference, showcasing its commitment to engaging with investors and stakeholders in the healthcare sector [1][2]. Company Overview - Telix is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals, addressing significant unmet medical needs in oncology and rare diseases [2]. - The company is headquartered in Melbourne, Australia, with operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan [2]. Upcoming Events - Kevin Richardson, CEO of Precision Medicine, will participate in a fireside chat with UBS on November 10, 2025, at 12:30 PM EST [1]. - Richard Valeix, CEO of Therapeutics, will engage in a fireside chat with Jefferies on November 18, 2025, at 10 AM GMT [2]. - Both sessions will be webcast live and accessible through Telix's Investor Relations website [2].

Company Overview - Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies [5] - The company is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan [5] - Telix aims to address significant unmet medical needs in oncology and rare diseases through its portfolio of clinical and commercial stage products [5] Investor Day Announcement - Telix will host an Investor Day on June 11, 2025, in New York City, focusing on growth opportunities in its commercial and clinical portfolio [1][2] - The event will feature presentations from key members of the Telix leadership team, including the Managing Director and Group CEO, Dr. Christian Behrenbruch, and other executives [3] - Key Opinion Leaders will also share insights on the clinical utility and opportunities for Telix's theranostic candidates during the event [3] Attendance Information - Attendance at the Investor Day is by invitation only for qualified institutional investors and analysts, and advance registration is required [4][5]